Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

MRP4 Modulation of the Guanylate Cyclase-C/cGMP Pathway: Effects on Linaclotide-Induced Electrolyte Secretion and cGMP Efflux.

Tchernychev B, Ge P, Kessler MM, Solinga RM, Wachtel D, Tobin JV, Thomas SR, Lunte CE, Fretzen A, Hannig G, Bryant AP, Kurtz CB, Currie MG, Silos-Santiago I.

J Pharmacol Exp Ther. 2015 Oct;355(1):48-56. doi: 10.1124/jpet.115.224329. Epub 2015 Jul 27.

PMID:
26216942
2.

Guanylate cyclase-C/cGMP: an emerging pathway in the regulation of visceral pain.

Hannig G, Tchernychev B, Kurtz CB, Bryant AP, Currie MG, Silos-Santiago I.

Front Mol Neurosci. 2014 Apr 16;7:31. doi: 10.3389/fnmol.2014.00031. eCollection 2014. Review.

3.

Gastrointestinal pain: unraveling a novel endogenous pathway through uroguanylin/guanylate cyclase-C/cGMP activation.

Silos-Santiago I, Hannig G, Eutamene H, Ustinova EE, Bernier SG, Ge P, Graul C, Jacobson S, Jin H, Liong E, Kessler MM, Reza T, Rivers S, Shea C, Tchernychev B, Bryant AP, Kurtz CB, Bueno L, Pezzone MA, Currie MG.

Pain. 2013 Sep;154(9):1820-30. doi: 10.1016/j.pain.2013.05.044. Epub 2013 Jun 5.

4.

Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation.

Busby RW, Kessler MM, Bartolini WP, Bryant AP, Hannig G, Higgins CS, Solinga RM, Tobin JV, Wakefield JD, Kurtz CB, Currie MG.

J Pharmacol Exp Ther. 2013 Jan;344(1):196-206. doi: 10.1124/jpet.112.199430. Epub 2012 Oct 22.

PMID:
23090647
5.

Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit.

Busby RW, Bryant AP, Bartolini WP, Cordero EA, Hannig G, Kessler MM, Mahajan-Miklos S, Pierce CM, Solinga RM, Sun LJ, Tobin JV, Kurtz CB, Currie MG.

Eur J Pharmacol. 2010 Dec 15;649(1-3):328-35. doi: 10.1016/j.ejphar.2010.09.019. Epub 2010 Sep 20.

PMID:
20863829
6.

Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract.

Bryant AP, Busby RW, Bartolini WP, Cordero EA, Hannig G, Kessler MM, Pierce CM, Solinga RM, Tobin JV, Mahajan-Miklos S, Cohen MB, Kurtz CB, Currie MG.

Life Sci. 2010 May 8;86(19-20):760-5. doi: 10.1016/j.lfs.2010.03.015. Epub 2010 Mar 20.

PMID:
20307554
7.

Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain.

Eutamene H, Bradesi S, Larauche M, Theodorou V, Beaufrand C, Ohning G, Fioramonti J, Cohen M, Bryant AP, Kurtz C, Currie MG, Mayer EA, Bueno L.

Neurogastroenterol Motil. 2010 Mar;22(3):312-e84. doi: 10.1111/j.1365-2982.2009.01385.x. Epub 2009 Aug 25.

PMID:
19706070
8.

Inhibition of filamentation can be used to treat disseminated candidiasis.

Saville SP, Lazzell AL, Bryant AP, Fretzen A, Monreal A, Solberg EO, Monteagudo C, Lopez-Ribot JL, Milne GT.

Antimicrob Agents Chemother. 2006 Oct;50(10):3312-6.

9.

The srhSR gene pair from Staphylococcus aureus: genomic and proteomic approaches to the identification and characterization of gene function.

Throup JP, Zappacosta F, Lunsford RD, Annan RS, Carr SA, Lonsdale JT, Bryant AP, McDevitt D, Rosenberg M, Burnham MK.

Biochemistry. 2001 Aug 28;40(34):10392-401.

PMID:
11513618
10.

Lipid modification of prelipoproteins is dispensable for growth in vitro but essential for virulence in Streptococcus pneumoniae.

Petit CM, Brown JR, Ingraham K, Bryant AP, Holmes DJ.

FEMS Microbiol Lett. 2001 Jun 25;200(2):229-33.

11.

A functional genomic analysis of type 3 Streptococcus pneumoniae virulence.

Lau GW, Haataja S, Lonetto M, Kensit SE, Marra A, Bryant AP, McDevitt D, Morrison DA, Holden DW.

Mol Microbiol. 2001 May;40(3):555-71.

12.

rho is not essential for viability or virulence in Staphylococcus aureus.

Washburn RS, Marra A, Bryant AP, Rosenberg M, Gentry DR.

Antimicrob Agents Chemother. 2001 Apr;45(4):1099-103.

13.

Characterization of the Streptococcus pneumoniae NADH oxidase that is required for infection.

Yu J, Bryant AP, Marra A, Lonetto MA, Ingraham KA, Chalker AF, Holmes DJ, Holden D, Rosenberg M, McDevitt D.

Microbiology. 2001 Feb;147(Pt 2):431-8.

PMID:
11158360
14.

Essentiality, expression, and characterization of the class II 3-hydroxy-3-methylglutaryl coenzyme A reductase of Staphylococcus aureus.

Wilding EI, Kim DY, Bryant AP, Gwynn MN, Lunsford RD, McDevitt D, Myers JE Jr, Rosenberg M, Sylvester D, Stauffacher CV, Rodwell VW.

J Bacteriol. 2000 Sep;182(18):5147-52.

15.

Identification, evolution, and essentiality of the mevalonate pathway for isopentenyl diphosphate biosynthesis in gram-positive cocci.

Wilding EI, Brown JR, Bryant AP, Chalker AF, Holmes DJ, Ingraham KA, Iordanescu S, So CY, Rosenberg M, Gwynn MN.

J Bacteriol. 2000 Aug;182(15):4319-27.

16.

The bacA gene, which determines bacitracin susceptibility in Streptococcus pneumoniae and Staphylococcus aureus, is also required for virulence.

Chalker AF, Ingraham KA, Lunsford RD, Bryant AP, Bryant J, Wallis NG, Broskey JP, Pearson SC, Holmes DJ.

Microbiology. 2000 Jul;146 ( Pt 7):1547-53.

PMID:
10878119
17.

A genomic analysis of two-component signal transduction in Streptococcus pneumoniae.

Throup JP, Koretke KK, Bryant AP, Ingraham KA, Chalker AF, Ge Y, Marra A, Wallis NG, Brown JR, Holmes DJ, Rosenberg M, Burnham MK.

Mol Microbiol. 2000 Feb;35(3):566-76.

18.

Selective potentiation of platinum drug cytotoxicity in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines by amphotericin B.

Sharp SY, Mistry P, Valenti MR, Bryant AP, Kelland LR.

Cancer Chemother Pharmacol. 1994;35(2):137-43.

PMID:
7987990

Supplemental Content

Loading ...
Support Center